MétaCan
Menu
← Back to cohort
Record W2980835666 · doi:10.1016/j.jalz.2019.06.4805

O4‐11‐06: NSAIDS FOR AD PREVENTION? NAPROXEN ENTERS THE CNS WITHOUT APPARENT EFFECT ON CSF IMMUNE MARKERS

2019· article· en· W2980835666 on OpenAlexaff
Pierre‐François Meyer, Anne Labonté, Pedro Rosa‐Neto, Judes Poirier, John C.S. Breitner

Bibliographic record

VenueAlzheimer s & Dementia · 2019
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsMcGill University Health CentreCenter for Diagnosis and Research on Alzheimer's DiseaseDouglas Mental Health University InstituteMcGill University
Fundersnot available
KeywordsNaproxenCerebrospinal fluidMedicineImmune systemPlaceboBiomarkerInternal medicineImmunologyPharmacologyGastroenterologyPathologyChemistry

Abstract

fetched live from OpenAlex

Epidemiological studies from the 1990’s and early 2000’s indicated an inverse association between non-steroidal inflammatory drug (NSAID) use and incidence of Alzheimer's disease (AD).[1] Subsequent clinical trials failed to confirm the benefits of NSAIDs and instead suggested harm.[2-4] The purported benefits of NSAIDs had been attributed to their anti-inflammatory activity, presumed to reduce AD-associated immune activation. However, there has never been any demonstration of NSAIDs’ ability to enter the human brain and affect immune mechanisms. Therefore, we conducted longitudinal investigations of cerebrospinal fluid (CSF) concentrations of the NSAID naproxen as well as several immune markers in INTREPAD, a randomized placebo-controlled trial of naproxen for prevention of AD biomarker progression among healthy elderly at increased risk for AD. Some 160 older adults with a parental or multiple-sibling family history of AD completed the two-year INTREPAD protocol. Of these 124 completed the trial on its prescribed dosage of naproxen 220 mg b.i.d. or placebo. Among these 78 had two or more lumbar punctures, permitting multiplex assay of cerebrospinal fluid (CSF) for 12 immune proteins and apolipoprotein E (apoE). Most of the CSF samples and concurrently collected plasma were also assayed for naproxen concentration using liquid chromatography with repeated mass spectroscopy. Naproxen was detected in plasma and CSF of naproxen-treated individuals only. However, CSF naproxen concentrations were ∼100 times lower than plasma concentrations (protein-bound fractions unknown). When present, CSF naproxen was associated with negligible change in CSF immune markers, but appeared to increase CSF apolipoprotein-E in proportion to drug concentration. Oral naproxen enters the CNS but induces negligible change in CSF immune markers. The disappointing efficacy results of AD prevention trials using naproxen and related drugs may therefore reflect limited blood-brain barrier transfer, or lack of the drugs’ effect on CNS immune processes. However, CSF apoE concentrations increased substantially over a two-year observation interval. This latter phenomenon appeared to be augmented in proportion to CSF concentration of naproxen. Overall, these findings suggest reconsideration of mechanistic assumptions regarding purported benefits of NSAIDs against AD risk. References: [1]int'Veld et al. N Engl J Med.2001;345:1515-21. [2]Aisen, et al. JAMA.2003;289:2819-26. [3]Thal, et al. Neuropsychopharmacology.2005;30:1204-15. [4]AdaptResearchGroup, et al. Neurology.2007;68:1800-8.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.319
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→